AAAAAA
Results: 1-25/33
Authors:
Danesi, R
De Braud, F
Fogli, S
Di Paolo, A
Del Tacca, M
Citation: R. Danesi et al., Pharmacogenetic determinants of anti-cancer drug activity and toxicity, TRENDS PHAR, 22(8), 2001, pp. 420-426
Authors:
Bocci, G
Fasciani, A
Danesi, R
Viacava, P
Genazzani, AR
Del Tacca, M
Citation: G. Bocci et al., In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels, MOL HUM REP, 7(8), 2001, pp. 771-777
Authors:
Di Paolo, A
Danesi, R
Falcone, A
Cionini, L
Vannozzi, F
Masi, G
Allegrini, G
Mini, E
Bocci, G
Conte, PF
Del Tacca, M
Citation: A. Di Paolo et al., Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients, ANN ONCOL, 12(9), 2001, pp. 1301-1306
Authors:
Fogli, S
Danesi, R
Braud, FD
Pas, TD
Curigliano, G
Giovannetti, E
Del Tacca, M
Citation: S. Fogli et al., Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer, ANN ONCOL, 12(11), 2001, pp. 1553-1559
Authors:
Bengala, C
Pazzagli, I
Innocenti, F
Donati, S
Favre, C
Menconi, MC
Greco, F
Danesi, R
Orlandini, C
Guarneri, V
Del Tacca, M
Conte, PF
Citation: C. Bengala et al., High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), ANN ONCOL, 12(1), 2001, pp. 69-74
Authors:
Falcone, A
Di Paolo, A
Masi, G
Allegrini, G
Danesi, R
Lencioni, M
Pfanner, E
Comis, S
Del Tacca, M
Conte, P
Citation: A. Falcone et al., Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients, J CL ONCOL, 19(15), 2001, pp. 3456-3462
Authors:
Conte, PF
Gennari, A
Donati, S
Salvadori, B
Baldini, E
Bengala, C
Pazzagli, I
Orlandini, C
Danesi, R
Fogli, S
Del Tacca, M
Citation: Pf. Conte et al., Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study, BREAST CANC, 68(2), 2001, pp. 171-179
Authors:
Natale, G
Lazzeri, G
Blandizzi, C
Gherardi, G
Lenzi, P
Pellegrini, A
Del Tacca, M
Citation: G. Natale et al., Seriate histomorphometry of whole rat stomach: An accurate and reliable method for quantitative analysis of mucosal damage, TOX APPL PH, 174(1), 2001, pp. 17-26
Authors:
Falcone, A
Allegrini, G
Masi, G
Lencioni, M
Pfanner, E
Brunetti, I
Danesi, R
Bocci, G
Del Tacca, M
Conte, P
Citation: A. Falcone et al., 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer, ONCOL-BASEL, 61(1), 2001, pp. 28-35
Authors:
Blandizzi, C
Colucci, R
Tognetti, M
De Paolis, B
Del Tacca, M
Citation: C. Blandizzi et al., H-3 receptor-mediated inhibition of intestinal acetylcholine release: pharmacological characterization of signal transduction pathways, N-S ARCH PH, 363(2), 2001, pp. 193-202
Authors:
Malizia, T
Batoni, G
Ghelardi, E
Baschiera, F
Graziani, F
Blandizzi, C
Gabriele, M
Campa, M
Del Tacca, M
Senesi, S
Citation: T. Malizia et al., Interaction between piroxicam and azithromycin during distribution to human periodontal tissues, J PERIODONT, 72(9), 2001, pp. 1151-1156
Authors:
Blandizzi, C
De Paolis, B
Colucci, R
Lazzeri, G
Baschiera, F
Del Tacca, M
Citation: C. Blandizzi et al., Comment on a published paper - Reply to Dobbs & Rivory, BR J PHARM, 134(2), 2001, pp. 449-450
Authors:
Blandizzi, C
De Paolis, B
Colucci, R
Lazzeri, G
Baschiera, F
Del Tacca, M
Citation: C. Blandizzi et al., Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan, BR J PHARM, 132(1), 2001, pp. 73-84
Authors:
Di Paolo, A
Danesi, R
Caputo, S
Macchia, M
Lastella, M
Boggi, U
Mosca, F
Marchetti, A
Del Tacca, M
Citation: A. Di Paolo et al., Inhibition of protein farnesylation enhances the chemotherapeutic efficacyof the novel geranylgeranyltransferase inhibitor BAL9611 colon cancer cells, BR J CANC, 84(11), 2001, pp. 1535-1543
Authors:
Danesi, R
Mosca, M
Boggi, U
Mosca, F
Del Tacca, M
Citation: R. Danesi et al., Genetics of drug response to immunosuppressive treatment and prospects forpersonalized therapy, MOL MED TOD, 6(12), 2000, pp. 475-482
Authors:
Bocci, G
Danesi, R
Di Paolo, A
Innocenti, F
Allegrini, G
Falcone, A
Melosi, A
Battistoni, M
Barsanti, G
Conte, PF
Del Tacca, M
Citation: G. Bocci et al., Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients, CLIN CANC R, 6(8), 2000, pp. 3032-3037
Authors:
Innocenti, F
Danesi, R
Favre, C
Nardi, M
Menconi, MC
Di Paolo, A
Bocci, G
Fogli, S
Barbara, C
Barachini, S
Casazza, G
Macchia, P
Del Tacca, M
Citation: F. Innocenti et al., Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: Implications for drug monitoring in children withacute lymphoblastic leukemia, THER DRUG M, 22(4), 2000, pp. 375-382
Authors:
Gennari, A
Donati, S
Danesi, R
Fogli, S
Orlandini, C
Del Tacca, M
Conte, PF
Citation: A. Gennari et al., The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer, SEMIN ONCOL, 27(1), 2000, pp. 14-19
Authors:
Di Paolo, A
Danesi, R
Nardini, D
Bocci, G
Innocenti, F
Fogli, S
Barachini, S
Marchetti, A
Bevilacqua, G
Del Tacca, M
Citation: A. Di Paolo et al., Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells, BR J CANC, 82(4), 2000, pp. 905-912
Authors:
Blandizzi, C
Lazzeri, G
Carignani, D
Colucci, R
Baschiera, F
Tognetti, M
Placanica, G
Del Tacca, M
Citation: C. Blandizzi et al., Peripheral cholecystokinin(A) and cholecystokinin(B) receptors mediate stimulation of gastric pepsinogen and acid secretion following intracerebroventricular injection of cholecystokinin-8-sulphate, ITAL J GAST, 31(6), 1999, pp. 440-448
Authors:
Gennari, A
Salvadori, B
Donati, S
Bengala, C
Orlandini, C
Danesi, R
Del Tacca, M
Bruzzi, P
Conte, PF
Citation: A. Gennari et al., Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors, J CL ONCOL, 17(11), 1999, pp. 3596-3602
Authors:
Innocenti, F
Danesi, R
Bocci, G
Fogli, S
Di Paolo, A
Del Tacca, M
Citation: F. Innocenti et al., Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens, CANC CHEMOT, 43(2), 1999, pp. 133-140
Authors:
Danesi, R
Conte, PF
Del Tacca, M
Citation: R. Danesi et al., Pharmacokinetic optimisation of treatment schedules for anthracyclines andpaclitaxel in patients with cancer, CLIN PHARMA, 37(3), 1999, pp. 195-211
Authors:
Del Tacca, M
Di Paolo, A
Danesi, R
Citation: M. Del Tacca et al., Clinical and preclinical pharmacology of Topotecan, TUMORI, 85(6), 1999, pp. S3-S11
Authors:
Fogli, S
Danesi, R
Innocenti, F
Di Paolo, A
Bocci, G
Barbara, C
Del Tacca, M
Citation: S. Fogli et al., An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma, THER DRUG M, 21(3), 1999, pp. 367-375